SARS-Cov-2 is a virus easily transmitted by air and fomites causing acute severe respiratory syndrome. Severity in some cases requires hospitalization and complex expensive intensive care treatments. Its rampant contagious led to a a fearful pandemic affecting the whole world with millions of infected humans and almost half a million deaths in a few months in the beginning of 2020 (until June 17, 2020). SARS-Cov2 is likely to have been spilled over from natural sylvatic cycles in bats from China. Our purpose is to comment on the human individual immune inflammatory responses to the infection of SARS-Cov2 and the reflections of these individual immunoinflammatory profiles on patterns of the severity of the disease, time for therapeutical intervention, pathogenesis, candidate drugs and indicative comparative drug prices for covid-19. Efficient treatment for covid-19 may require: 1) early disease detection, 2) a combination of drugs being used for 3) targeting the virus replication cycle and 4) specific/ individualized drug treatment for given immunoinflammatory human profile responses in a 5) timely manner. Specific serum immuno-markers of covid-19 affected individuals at onset, in the follow-up, and in the resolution of the immunoinflammatory storm during the course of the disease may lead to individualized therapeutics with better outcomes. Covid-19 is unlikely to be the last emergent human disease with fast pandemic potencial. To gather knowledge on the human host profiles and immunoinflamatory responses is an opportunity that could pave the way to faster, more efficient strategies to tackle upcoming diseases.
The severity of SARS-CoV2 infection, Covid19 disease, should account for the diversity of human individual immunoinflammatory responses. Serum immunological markers during Covid19 illness may lead to individualized therapeutics with better outcomes. Efficient treatment for Covid19 may require: 1) early disease detection, 2) combineddrug therapy for 3) targeting the virus replication cycle, and 4) individualized drug treatment for specific immunoinflammatory human profile responses administered in a 5) timely manner. Covid19 is unlikely to be the last emergent human disease with fast pandemic potential. Gathering knowledge on the individual human host profilesof immunoinflammatory responses is an opportunity that could lead us to understand individual differences in response to infection at the individual and population level, paving the way to faster, more efficient strategies to tackle upcoming infectious diseases. This is a position paper based on an integrative non-exhaustive literature revision.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.